COVİD-19 Salgınında Gündeme Gelen Nadir Enfeksiyon Mukormikoza Genel Bir Bakış
Mukormikoz özellikle immunkompromize hasta grubunda çeşitli klinik tablolara yol açan akut seyirli ve mortalitesi yüksek fırsatçı bir enfeksiyondur. İnvaziv fungal enfeksiyonlar içinde aspergillus ve candida enfeksiyonlarından sonra üçüncü sırada yer alır. Covid-19 salgını sırasında Hindistan’da ani artış gösteren ve endişe yaratan mukormikoz vakaları hastalığın tedavisinde uygulanan immunsupresif tedavilerle ilişkilendirilmiş, Covid-19 vakalarında prevelansı %0,3-%0,8 saptanmıştır.Mukormikozun tanı ve tedavisinde, ilerlemelere rağmen mortalite halen oldukça yüksek (%40-80) olup riskli hasta gruplarında, mukormikozun akılda tutulması erken tanı için önemlidir.
AN OVERVIEW OF THE RARE INFECTION MUCORMICOSIS WHICH COMES TO THE AGENDA DURING COVID-19 OUTBREAK
___
- Kaynaklar
1.Kauffman CA, Malani AN. Zygomycosis: an emerging
fungal infection with new options for management. Curr
Infect Dis Rep 2007; 9:435.
- 2.Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM,
Arastehfar A, Gangneux JP, et al. The emergence of
COVID-19 associated mucormycosis: a review of cases
from 18 countries. Lancet Microbe. 2022;3:543-52.
- 3.Kontoyiannis DP, Lewis RE. Agents of mucormycosis
and Entomophthoramycosis. In: Mandell GL, Bennett JE,
Dolin R, editors. Principles and Practice of Infectious
Diseases. 9th ed.New York, USA: Churchill Livingstone;
2019. P.3117-3130.
- 4.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA,
Sarkisova TA, Schaufele RL, et al. Epidemiology and
outcome of zygomycosis: a review of 929 reported
cases. Clin Infect Dis. 2005;41:634-53.
- 5.Gale GR, Welch AM. Studies of opportunistic fungi. I.
Inhibition of Rhizopus oryzae by human serum. Am J Med
Sci. 1961;241:604-12.
- 6.Shinde RV, Karande GS, Mohite ST, Patil SR.
Rhino-orbital mucormycosis in diabetes mellitus. J Clin
Diagn Res. 2013;7:1145-7
- 7.McNulty JS. Rhino-cerebral mucormycosis:
predisposing factors. Laryngoscope. 1982;92:1140-3.
- 8.Manjunath KS, Shivaswamy S, Kulkarni JD, Kenkare
Venkatachalaiah R. Rhino-orbito-cerebral mucormycosis
(ROCM) with internal carotid artery stenosis in a diabetic
patient with caries tooth and oroantral fistula. BJR Case
Rep. 2016 ;2:20150447
- 9.Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder
SD, Lowe JE. Pulmonary mucormycosis: results of
medical and surgical therapy. Ann Thorac Surg.
1994;57:1044-50.
- 10.Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis
DP. The diagnostic value of halo and reversed halo signs
for invasive mold infections in compromised hosts. Clin
Infect Dis. 2011;52:1144-55
- 11.Chamilos G, Marom EM, Lewis RE, Lionakis MS,
Kontoyiannis DP. Predictors of pulmonary zygomycosis
versus invasive pulmonary aspergillosis in patients with
cancer. Clin Infect Dis. 2005;41:60-6.
- 12.Agha FP, Lee HH, Boland CR, Bradley SF.
Mucormycoma of the colon: early diagnosis and
successful management. AJR Am J Roentgenol.
1985;145:739-41
- 13.Didehdar, M., Moradabadi A, Anoushirvani AA,
Tabaeian SP, Yousefimashouf M, Shariati A.
Gastrointestinal mucormycosis: a periodic systematic
review of case reports from 2015 to 2021. Microbial
Pathogenesis, 2022;163:105388
- 14.Kato H, Foster CM, Karri K. Incidence, predisposing
conditions and outcomes of cutaneous mucormycosis: a
national database study. Mycoses, 2021;64:569-72.
- 15.Levy E, Bia MJ. Isolated renal mucormycosis: case
report and review. J Am Soc Nephrol. 1995;5:2014-9.
- 16.Hopkins RJ, Rothman M, Fiore A, Goldblum SE.
Cerebral mucormycosis associated with intravenous drug
use: three case reports and review. Clin Infect Dis.
1994;19:1133-7.
- 17.Siddiqi SU, Freedman JD. Isolated central nervous
system mucormycosis. South Med J.
1994;87:997-1000.
- 18.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA,
Sarkisova TA, Schaufele RL, et al. Epidemiology and
outcome of zygomycosis: a review of 929 reported
cases. Clin Infect Dis. 2005;41:634-53.
- 19.Machouart M, Larché J, Burton K, Collomb J, Maurer
P, Cintrat A, et al. Genetic identification of the main
opportunistic Mucorales by PCR-restriction fragment
length polymorphism. J Clin Microbiol. 2006;44:805-10.
- 20.Schrödl W, Heydel T, Schwartze VU, Hoffmann K,
Grosse-Herrenthey A, Walther G, et al. Direct analysis
and identification of pathogenic Lichtheimia species by
matrix-assisted laser desorptionionization-time of flight
analyzer-mediated mass spectrometry. J Clin Microbiol.
2012;50:419-27.
- 21.Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen
SCA, Dannaoui E, Hochhegger B, et al. Global guideline
forthe diagnosis and management of mucormycosis: an
initiative of the European Confederation of Medical
Mycology in cooperation with the Mycoses Study Group
Education and Research Consortium. Lancet Infect Dis.
2019;19:e405-21.
- 22.Levy E, Bia MJ. Isolated renal mucormycosis: case
report and review. J Am Soc Nephrol. 1995;5:2014-9.
- 23.Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M,
Pangal E, et al. Susceptibility of severe COVID-19
patients to rhino-orbital mucormycosis fungal infection in
different clinical manifestations. Jpn J Ophthalmol.
2021;65:515-25.
- 24.Ibrahim AS, Bowman JC, Avanessian V, Brown K,
Spellberg B, Edwards JE, et al. Caspofungin inhibits
Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers
burden in brain measured by quantitative PCR, and
improves survival at a low but not a high dose during
murine disseminated zygomycosis. Antimicrob Agents
Chemother. 2005;49:721-7.
- 25.Ramadorai A, Ravi P, Narayanan V. Rhino-cerebral
mucormycosis: a prospective analysis of an effective
treatment protocol. Ann Maxillofac Surg. 2019;9:192-6
- 26.Kontoyiannis DP, Lewis RE. How I treat
mucormycosis. Blood. 2011;118:1216-24.